Curative resection

PROCEDURE3 trials

Sponsors

Jia Fan, Samsung Medical Center, The Catholic University of Korea

Conditions

Colon Cancer, ObstructionCurable Hepatitis B Virus-Related Hepatocellular CarcinomaStage IIIA Non-small Cell Lung Cancer

Phase 2

Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients

Samsung Medical CenterStage IIIA Non-small Cell Lung Cancer

Start: 2017-02-14End: 2021-08-13Target: 37Updated: 2017-02-15

Phase 4

Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection

Jia FanCurable Hepatitis B Virus-Related Hepatocellular Carcinoma

Start: 2015-01-31End: 2018-10-31Target: 360Updated: 2014-11-21

Unknown Phase

Outcome of Neoadjuvant Chemotherapy for Obstructive Colon Cancer

Not yet recruitingNCT04889820

The Catholic University of KoreaColon Cancer, Obstruction

Start: 2021-11-01End: 2027-10-31Target: 204Updated: 2021-09-22

Related Papers

Oncologic oUTcomes of neoadjuvant chemotherapy for obSTructive colon cAncer after steNt decompression (OUTSTAND trial); A study protocol of multicenter non-inferiority randomized controlled trial.

2025-02-03

Phase II, prospective single-arm study of adjuvant pembrolizumab in N2 positive non-small cell lung cancer (NSCLC) treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection: Preliminary results.

Journal of Clinical Oncology2019-05-205 citations

A multicenter, randomized, observation-controlled clinical trial to evaluate the efficacy and safety of thymalfasin adjuvant therapy in patients with HBV-related HCC after curative resection – first announcement of the protocol

Expert Opinion on Biological Therapy2015-06-2210 citations